Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
On Monday, H.C. Wainwright analysts assumed coverage of Sensei Biotherapeutics (NASDAQ: SNSE) stock with a Buy rating, setting a price target of $5.00. The analysts highlighted Sensei’s innovative approach to developing immune checkpoint inhibitors as a key reason for the positive outlook. Currently trading at $0.30, the stock appears undervalued according to InvestingPro analysis. The company maintains a healthy balance sheet with more cash than debt and a current ratio of 6.82x.
Sensei Biotherapeutics is focused on creating conditionally active antibodies that function selectively in tumor microenvironments. The company’s lead product, solnerstotug (formerly known as SNS-101), is a monoclonal antibody targeting the V-domain Ig suppressor of T-cell activation (VISTA).
The antibody is engineered to selectively target active VISTApH6.0 in tumor microenvironments, as opposed to VISTApH7.4 in peripheral areas. This targeting mechanism is designed to enhance the efficacy of the treatment in solid tumors.
Initial data from a Phase 1/2 trial of solnerstotug has shown promising clinical efficacy. The potential approval of this antibody could mark it as the first anti-VISTA monoclonal antibody to be used as a therapeutic agent. With a market capitalization of just $7.6 million and unanimous analyst Buy ratings, investors seeking detailed analysis can explore additional metrics on InvestingPro.
In other recent news, Sensei Biotherapeutics announced significant developments at its annual stockholders meeting, where key proposals were approved. The election of two board directors, William Ringo and John Celebi (IS:CLEBI), was confirmed, with a notable number of broker non-votes. Deloitte & Touche LLP was ratified as the company’s independent auditor for the fiscal year ending December 31, 2025. Additionally, shareholders approved an amendment for a reverse stock split, allowing flexibility in the company’s share structure. Sensei Biotherapeutics also shared promising preliminary results from its Phase 1/2 trial of solnerstotug, a new cancer therapy. The trial showed a 14% overall response rate in patients resistant to PD-(L)1 inhibitors, with a durable complete response observed in a Merkel Cell Carcinoma patient. H.C. Wainwright reaffirmed a Buy rating and a $4 price target for Sensei, citing these trial findings. The company plans to initiate a Phase 2 study in early 2026, which will focus on biomarker-based patient selection to optimize outcomes. These developments highlight Sensei’s ongoing efforts to advance its cancer therapy pipeline and strengthen its corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.